18-Year-Old Undergoes 3 Brain Surgeries from Blood Clots after J&J Vaccine
DEBATING COVID-19, 26 Apr 2021
A Nevada teen was put in a coma, placed on a respirator and underwent three brain surgeries after developing blood clots about one week after getting the Johnson & Johnson vaccine.
21 Apr 2021 – A Nevada teen who received Johnson & Johnson’s (J&J) COVID vaccine on April 1 underwent three brain surgeries to repair blood clots she developed about a week after receiving the vaccine, Las Vegas Review-Journal reported.
According to family spokesperson Bret Johnson, after Emma Burkey, 18, suffered seizures, doctors placed her in an induced coma and on a respirator. The high school senior has improved and is now awake and off the respirator, but still requires a tracheostomy tube, which has impaired her ability to speak.
“She is improving slowly,” Johnson told Las Vegas Review-Journal. “The word we got from her parents last night was ‘slowly, slowly slowly.’ For a while there, her situation and condition was completely unknown. Very scary and very iffy, honestly.”
Although Burkey experienced a “massive brain injury,” her parents are “cautiously optimistic,” Johnson said.
Burkey was first treated at St. Rose Dominican Hospital in Henderson before being airlifted to Loma Linda University Medical Center in Southern California for specialized care.
The woman, identified as 18-year-old Emma Burkey, was one of six women across the country who experienced a serious clotting side effect after receiving the one-shot vaccine.https://t.co/0yACTBhySQ
— FOX5 Las Vegas (@FOX5Vegas) April 20, 2021
A Centers for Disease Control and Prevention (CDC) panel said Burkey and other women experienced headaches and back pain prior to the discovery of blood clots.
The CDC panel also disclosed that Burkey was given heparin, a blood thinner which typically is standard treatment for blood clots, but in cases like Burkey’s, can actually make the condition worse.
“If someone comes in with this really rather rare syndrome of thrombotic thrombocytopenia where you get thromboses, the most common way to treat that would be with heparin,” White House Chief Medical Advisor Dr. Anthony Fauci said during an April 13 White House news briefing. “That would be a mistake in this situation because that could be dangerous and make the situation worse.”
As The Defender reported April 16, Children’s Health Defense queried data from the CDC’s Vaccine Adverse Events Reporting System (VAERS) for events associated with clotting disorders. VAERS yielded a total of 795 reports for all three vaccines from Dec. 14, 2020, through April 8. Of the 795 cases reported, there were 400 reports attributed to Pfizer, 337 reports to Moderna and 56 reports associated with J&J.
U.S. health authorities recommended a pause for J&J vaccinations last week while they investigate reports of what they described as “rare and severe” clot conditions. The CDC’s Advisory Committee on Immunization Practices is scheduled to meet Friday to consider whether to resume vaccinations with J&J’s single-dose shot, and if so, what recommendations or restrictions for use should be put in place.
The European Medicines Agency said Tuesday its safety committee recommended a warning about a rare, serious blood-clot condition be added to the product information for J&J’s vaccine. The agency, which oversees drug regulation in the EU, said the benefits still outweigh the risks of the vaccine, but noted people should be aware of rare blood clot symptoms so they can quickly get treated if they develop symptoms.
Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.
Tags: AstraZeneca Vaccine, Big Pharma, COVID-19, Conflict, Coronavirus, Corruption, Elites, Johnson and Johnson Vaccine, Medical Industrial Complex, Moderna vaccine, Pfizer vaccine, Vaccine Apartheid, Vaccines
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Join the discussion!
We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.
Click here to go to the current weekly digest or pick another article: